Nkarta presents nkx101 clinical data at the 2023 american society of hematology annual meeting & exposition

South san francisco, calif., dec. 09, 2023 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a clinical-stage biopharmaceutical company developing engineered natural killer (nk) cell therapies, today announced a poster presentation at the 2023 american society of hematology (ash) annual meeting and exposition featuring follow-up data from its phase 1 clinical trial that evaluates nkx101 in patients with relapsed or refractory acute myeloid leukemia (r/r aml). nkx101 is an allogeneic, off-the-shelf nk cell therapy candidate derived from healthy donors and engineered to target nkg2d ligands.
NKTX Ratings Summary
NKTX Quant Ranking